# ADTRAN Holdings, Inc. (ADTN) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/adtn/thesis · /memo/adtn

## Financial Snapshot

---
source: coverage-next-full
ticker: ADTN
company: ADTRAN Holdings, Inc.
step: 04
title: Financial Quality & Adversarial Sweep
created: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Sweep: ADTRAN Holdings, Inc. (ADTN)

#### S1 — Financial Statement Quality Assessment

##### Income Statement Quality

**Revenue recognition:** ADTRAN recognizes revenue under ASC 606 (adopted 2018). Revenue is recognized at point-in-time for hardware and ratably for support/maintenance contracts. No material restatements identified. Deferred revenue growing ($52.7M → $87.5M FY2024 → FY2025) is consistent with growing subscription mix — a sign of revenue quality improvement. [S1: 10-K FY2025; StockAnalysis.com]

**Goodwill impairment:** The $297.4M goodwill impairment in Q1 2024 and prior $268.9M net loss in FY2023 (which included approximately $217M impairment in that year per 10-K FY2023 summary) are non-cash charges tied to ADVA merger price paid vs. subsequent enterprise value. Post-impairment goodwill balance is $60M (FY2025), creating minimal additional impairment risk going forward. [S2: xbrl_summary.md]

**Amortization of intangibles:** ADTRAN carries $294M in other intangible assets (FY2025), which it is amortizing. D&A was $92.6M in FY2025, of which a substantial portion is intangible amortization (estimated $65-70M). This creates a persistent GAAP/non-GAAP gap. The amortization schedule will decline as these assets age, providing a natural tailwind to GAAP earnings over 3-5 years. [Estimate; S3: stockanalysis_summary.md]

**SBC:** $10.1M in FY2025 (down from $28.3M in FY2022). Represents ~0.9% of revenue — modest and declining. [S4: xbrl_summary.md]

##### Balance Sheet Quality

**Equity erosion:** Shareholders' equity declined from $1,303.6M (FY2022, immediately post-merger) to $145.8M (FY2025) — a 89% decline driven entirely by cumulative GAAP losses ($2M + $268.9M + $459.9M + $45.7M = ~$776.5M cumulative net losses FY2022-FY2025). Tangible book value is negative (-$2.61/share). This is a red flag for GAAP book value analysis but is fully explained by the non-cash nature of the losses. [S5: XBRL; StockAnalysis.com]

**Inventory:** Normalized from $427.5M peak (FY2022 — supply chain over-ordering) to $215.7M (FY2025). The $211.8M decline in inventory from peak represents cash that was locked in excess stock and is now being unwound. Inventory days remain elevated relative to pre-merger norms but are trending correctly. [S6: stockanalysis_summary.md balance sheet]

**Accounts receivable:** $210.7M (FY2025). Days Sales Outstanding estimated at ~70 days — within normal range for B2B equipment vendors. No material DSO extension noted. [Estimate; S7: stockanalysis_summary.md]

**Debt maturity:** Long-term debt $218M under Wells Fargo credit facility; revolving capacity $319.2M available. No near-term maturity cliff. [S8: 10-K FY2025]

##### Cash Flow Quality

**OCF/Net Income divergence:** OCF was +$129.8M in FY2025 vs. net loss of ($45.7M). The gap of $175.5M is explained by D&A ($92.6M), SBC ($10.1M), and working capital tailwind (inventory drawdown). This OCF level is credible given the trajectory of inventory normalization. [S9: StockAnalysis.com CF statement]

**FCF consistency:** FCF positive in both FY2024 ($69.1M) and FY2025 ($98.1M). This two-year track record of FCF positivity despite GAAP losses is the most important indicator of business quality improvement post-merger. [S10: XBRL; StockAnalysis.com]

**CapEx structure:** CapEx $31.7M (2.9% of revenue) + R&D capitalization $37.5M = total investing cash outflows ~$69M. The relatively low CapEx intensity reflects ADTRAN's asset-light manufacturing model (contract manufacturing). [S11: StockAnalysis.com CF]

#### S2 — Statement-Quality Adjustments

| Item | GAAP Treatment | Economic Reality | Adjustment |
|------|---------------|-----------------|-----------|
| Intangible amortization | Expense (~$65-70M est.) | Non-cash; from ADVA acquisition price | Add back to get economic operating margin |
| Goodwill impairment | Expense ($297.4M in FY2024) | Non-recurring; total impairment now booked | Exclude from recurring earnings |
| Restructuring charges | Expense ($40.5M FY2024; ~$0 FY2025) | Substantially non-recurring (BEP complete) | Exclude from recurring |
| SBC | Expense ($10.1M) | Dilutive but ongoing | Include in economic cost |
| Deferred revenue growth | Not on IS | Leading indicator of software contract bookings | Positive quality signal |
| Inventory normalization | Working capital source | Cash recovered, one-time benefit | Quality: neutral (correctly counts as OCF) |

**Adjusted Operating Income (FY2025 Estimate):**
- GAAP Operating Income: ($15.6M)
- + Intangible amortization: ~$65M [Estimate]
- + Restructuring: ~$0
- = **Adjusted Operating Income: ~$49.4M** (~4.6% adjusted margin)
- Non-GAAP operating margin per management: 4.6%-4.9% ✓ [S12: investor_presentation_2024.md]

#### S3 — Adversarial Research Sweep

*Per the output contract, this section identifies short reports, investigations, lawsuits, and negative narratives that constitute a credible bear case. Sources: SEC filings, web search of recent news and investigations.*

##### Finding 1: DPLTA Minority Appraisal Proceedings (MEDIUM RISK)

**Nature:** The Domination and Profit and Loss Transfer Agreement (DPLTA) between ADTRAN Holdings and Adtran Networks SE provided an exit compensation mechanism for Adtran Networks SE minority shareholders (€8.58/share). Certain minority shareholders are challenging this compensation in German court (Spruchverfahren) as inadequate. As of FY2025, ~$17.4M has been paid in exit compensation; additional amounts could be required depending on court outcome.

**Risk Assessment:** Financial exposure is real but bounded. The proceedings are disclosed in 10-K risk factors. Resolution is expected by ~2027. The worst-case incremental liability is likely in the $20-50M range [Estimate; not a company disclosure], manageable given FCF trajectory. This is a known risk fully reflected in the stock discount from intrinsic value estimates.

**Source:** ADTRAN 10-K FY2025 Risk Factors; xbrl_summary.md [S13]

##### Finding 2: FY2024 Goodwill Impairment — Management Credibility at Initial Guidance

**Nature:** When ADTRAN completed the ADVA merger in 2022, management paid a premium price that ultimately proved too high — by Q1 2024, they impaired $297.4M of goodwill. This signals that post-merger integration was more difficult and the acquired business less valuable than initial underwriting assumed.

**Risk Assessment:** This is a retrospective credibility issue, not an ongoing risk. Importantly, the impairment is now fully booked ($60M goodwill remaining) and no additional impairment occurred in FY2025 despite continued losses. Management has since successfully executed the Business Efficiency Program (workforce reduction, SG&A rationalization) that turned OCF positive and is driving margin recovery. The goodwill impairment history is a reason for discount to management guidance credibility on forward estimates, but not a current operating risk. [S14: 10-K FY2024]

##### Finding 3: Revenue Cyclicality — FY2024 Telecom Capex Downcycle

**Nature:** ADTRAN's FY2024 revenue declined 19.7%, driven by major telecom operators pausing equipment purchases to work through excess inventory accumulated during the post-pandemic supply chain boom. This cyclicality is structural to the equipment sector.

**Risk Assessment:** The risk of another inventory-correction cycle exists if operators over-order for BEAD projects in 2026-2027. However, the FY2024 correction was an inventory digestion event (not demand destruction), and the normalized demand base appears intact given FY2025 recovery. [S15: 10-K FY2024 MD&A]

##### Finding 4: No Material Short Reports or Investigations Found

A search for short reports (Hindenburg, Citron, etc.), SEC investigations, DOJ proceedings, material related-party transactions, or accounting fraud allegations for ADTRAN Holdings returned no material findings as of June 2026. The company is a long-standing Nasdaq-listed equipment vendor with a clean regulatory history at the ADTRAN, Inc. entity level; no material adverse forensic findings.

**Note:** The combined entity (ADTRAN Holdings) is relatively new (FY2022); the German entity (Adtran Networks SE) has separate governance and regulatory obligations in Germany. No German regulatory adverse findings identified.

##### Finding 5: Equity Base Thinness — Binary Risk in Severe Downside

**Nature:** Total equity of $145.8M against $685M in total liabilities creates thin balance sheet coverage. A severe revenue downturn (>25%) combined with continued cash burn would risk covenant violations or liquidity stress.

**Risk Assessment:** This risk is mitigated by: (1) $319M available credit facility, (2) FCF positive at $98M, (3) no near-term debt maturities. The business would need to lose ~$100M of FCF annually for 2+ years to create genuine covenant risk — unlikely given the recovery trajectory and BEAD tailwind. Not a current concern; a bear-case scenario risk. [S16: 10-K FY2025 liquidity section]

#### S4 — Quality Scorecard

| Dimension | Grade | Notes |
|-----------|-------|-------|
| Revenue recognition | B+ | ASC 606 compliant; deferred revenue growing (positive) |
| Earnings quality | B | GAAP losses non-cash heavy; FCF credible |
| Balance sheet | C+ | Equity thin; debt manageable; inventory normalized |
| Cash flow quality | A- | OCF/FCF positive 2-year track; credible build |
| Governance/transparency | B | No adverse forensic; DPLTA litigation disclosed fully |
| Management credibility | B- | BEP execution = positive; ADVA underwrite = negative |
| **Overall** | **B** | Post-merger recovery with credible cash economics |

#### Source Index

| ID | Source |
|----|--------|
| S1 | ADTRAN 10-K FY2025; StockAnalysis.com balance sheet |
| S2 | xbrl_summary.md — goodwill impairment data |
| S3 | stockanalysis_summary.md — D&A, intangibles |
| S4 | xbrl_summary.md — SBC data |
| S5 | XBRL; StockAnalysis.com — equity history |
| S6 | stockanalysis_summary.md — inventory history |
| S7 | stockanalysis_summary.md — AR |
| S8 | ADTRAN 10-K FY2025 — liquidity |
| S9 | StockAnalysis.com — annual CF statement |
| S10 | XBRL; StockAnalysis.com — FCF FY2024/FY2025 |
| S11 | StockAnalysis.com — investing CF |
| S12 | investor_presentation_2024.md — non-GAAP reconciliation |
| S13 | ADTRAN 10-K FY2025 Risk Factors — DPLTA proceedings |
| S14 | ADTRAN 10-K FY2024 — goodwill impairment |
| S15 | ADTRAN 10-K FY2024 MD&A |
| S16 | ADTRAN 10-K FY2025 — liquidity and capital resources |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ADTN/fundamental

## Navigation

- Overview: /stocks/adtn
- Financials (this page): /stocks/adtn/financials
- Thesis: /stocks/adtn/thesis
- Investment Memo: /memo/adtn
- Coverage universe: /stocks